BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 28212972)

  • 1. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
    Kawalec P; Sagan A; Pilc A
    Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of health technology assessment reports on decision making in Austria.
    Zechmeister I; Schumacher I
    Int J Technol Assess Health Care; 2012 Jan; 28(1):77-84. PubMed ID: 22233544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Market uptake of orphan drugs--a European analysis.
    Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
    J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Market access to new anticancer medicines for children and adolescents with cancer in Europe.
    Schoot RA; Otth MA; Frederix GWJ; Leufkens HGM; Vassal G
    Eur J Cancer; 2022 Apr; 165():146-153. PubMed ID: 35235871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
    Leyens L; Brand A
    Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient advocacy group involvement in health technology assessments: an observational study.
    Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
    Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
    García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
    Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
    Lipska I; McAuslane N; Leufkens H; Hövels A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.
    Gulácsi L; Rotar AM; Niewada M; Löblová O; Rencz F; Petrova G; Boncz I; Klazinga NS
    Eur J Health Econ; 2014 May; 15 Suppl 1():S13-25. PubMed ID: 24832832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
    Allen N; Liberti L; Walker SR; Salek S
    Front Pharmacol; 2017; 8():384. PubMed ID: 28713265
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
    Kolasa K; Kalo Z; Zah V; Dolezal T
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.